Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 83.88

+2.4%

Jan 29 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sds who wrote (1922)	4/9/1998 10:51:00 PM
From: ewolf	Read Replies (1) of 4676

Listened to the company's conference call. Their view is that the drug can be approved before the end of the year. They have not applied for fast track status but they believe that the fda has indicated that they are on the same time frame as fast track. Fomivirsen seems to be the superior drug for cmv by a wide margin. Isis thinks that cmv will occur more frequently in the furture and the drug may have a significant enough market. Regardless, they get milestone payments and other support from Ciba. Also said that the issue with the fda of antisense technology is basically behind the company. Isis has had an ongoing dialogue with the fda during the development of the drug which has been useful for the company. The fda understands the technology according to Isis. Isis may not become a major pharmaceutical overnight but their potential seems stronger than ever if one can view them apart from the price of their stock.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next